NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Collaborates on Clinical Biomarker Research  - Thermo Fisher Scientific, Inc., and Professor Bruno Domon, director of the new Luxembourg Clinical Proteomics unit (LCP), announced a collaboration to develop workflows that overcome current bottlenecks
Thermo Fisher Scientific Collaborates on Clinical Biomarker Research

 

NewswireTODAY - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2010/04/22 - Thermo Fisher Scientific, Inc., and Professor Bruno Domon, director of the new Luxembourg Clinical Proteomics unit (LCP), announced a collaboration to develop workflows that overcome current bottlenecks.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific Inc., the world leader in serving science, and Professor Bruno Domon, director of the new Luxembourg Clinical Proteomics unit (LCP), today announced a collaboration to develop workflows that overcome current bottlenecks in biomarker discovery and assay development for clinical proteomics research. The LCP is funded by the Fonds National de la Recherch and is hosted at Public Research Centre for Health (CRP-Santé).

Thermo Fisher has collaborated with Bruno Domon since 2007, and previous joint work has led to the development of original and exciting proteomics approaches for biomarker discovery and verification. Foremost among these is the cutting-edge intelligent Selected Reaction Monitoring (iSRM) technology now incorporated within the Thermo Scientific TSQ family of triple quadrupole mass spectrometers. iSRM reduces acquisition times for each peptide analyzed in a peptide biomarker panel, allowing both improved quantification and confirmation of the identity of the peptide being quantified. In addition to his part in developing iSRM, Bruno Domon was a primary scientific contributor to the Thermo Scientific Pinpoint software, which simplifies the creation of quantitative peptide assays on Thermo Scientific TSQ mass spectrometers and allows researchers to leverage knowledge acquired in previous qualitative proteomics discovery experiments.

Bruno Domon was recently appointed director of LCP initiative at CRP- Santé. He has established a biomarker research group that is active in clinical proteomics with a strong focus today on biomarker verification and plans to encompass metabolomics in the near future. The CRP-Santé research group will employ the recently introduced Thermo Scientific LTQ Orbitrap Velos hybrid mass spectrometer equipped with electron transfer dissociation (ETD) for biomarker discovery. This latest-generation hybrid linear ion trap-Orbitrap instrument is more accurate, faster and more sensitive than older generation LTQ Orbitrap instruments. It enables the massive, rapid and accurate identification of proteins in complex mixtures and the characterization of post-translational modifications. These capabilities are central to the creation of a second-generation biomarker discovery and validation workflow. In addition, the group will utilize the Thermo Scientific TSQ Vantage triple stage quadrupole mass spectrometer for fast, sensitive, accurate and reliable targeted protein quantification, and it will use Pinpoint software for rapid, automated assay development. The Thermo Scientific Exactive benchtop LC/MS mass spectrometer, which leverages proven Orbitrap™ technology, will be employed for biomarker profiling analyses.

“As a market leader in the development of tools for proteomics research, Thermo Fisher was the clear choice for collaborating on these clinical projects,” said Bruno Domon. “By joining forces, I hope to build on our results to further develop workflows that will enable researchers to overcome challenges in biomarker discovery and verification.”

“Bruno Domon is a leading researcher in proteomics, and his academic and industrial experience complements Thermo Fisher’s commitment to producing proteomics solutions,” said Ian Jardine, vice president of global R&D for Thermo Fisher Scientific. “This collaboration provides a unique opportunity for the company to expand its role in the development of cutting-edge biomarker research tools and consolidate its presence within the EU.”

The newly established biomarker research group within CRP-Santé is part of a wider effort in Luxembourg to develop projects that are at the forefront of biomedical research. This effort includes the Integrated Biobank (IBBL) of Luxembourg, a state-of-the-art tissue storage and distribution initiative designed to help a worldwide network of cancer scientists and other disease researchers find answers to the world’s most pressing health problems.

Overall, the Luxembourg government-led initiative, launched in 2008, is expected to support the development of cutting-edge skills and expertise in the field of molecular medicine. The objective is not only to strengthen the national research effort and benefit the country’s healthcare system,, but also to foster the diversification of Luxembourg’s economic fabric in a promising and fast-growing sector. The research collaboration between Thermo Fisher Scientific and CRP-Santé substantiates this strategy and constitutes a first important milestone towards its implementation.

For more information on Thermo Scientific mass spectrometry solutions for biomarker research, please call 800-532-4752, email analyze[.]thermofisher.com.

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

About CRP-Santé - Luxembourg Clinical Proteomics (LCP)
CRP-Santé employs 200 researchers and 50 support staff, working on some hundred research projects which resulted in 98 peer-reviewed publications in the year 2009. Its annual budget is currently around 35 million Euros, increasing each year.

CRP-Santé actively interacts with multiple international collaborations, the most relevant in the context of current proposal being the partnerships with TGen Foundation in Phoenix, Arizona (tgen.org) and with the Fred Hutchinson Cancer Research Center in Seattle, Washington.

CRP-Santé (crp-sante.lu) is a young research organisation with highly qualified personnel working in multidisciplinary teams with strong integration of laboratory, clinical and public health research. CRP-Santé’s research focus is on health topics with high impact on the European population. The research units have state-of-the-art equipment in emerging fields of biomedical research and increasingly develop a market orientation aiming at commercial and clinical valorisation.

Luxembourg Clinical Proteomics (LCP) was created in December 2009 and has been funded by the Fonds National de la Recherche (FNR), with a start-up grant of 5 million Euros and a development plan for the next five years. A research group in is being recruited to launch the Luxembourg Clinical Proteomics Initiative in the next couple of months.

Bruno Domon, Head of the Luxembourg Clinical Proteomics Initiative (LCP) is relocating from ETH–Zurich (Prof. Ruedi Aebersold group) and has a wide scientific experience in academia: University of Lausanne, MIT Cambridge MA, University of Lille, France; and ETH Zurich) and in the private sector: Ciba/Novartis, Basel; Biogen, Cambridge MA; and Celera Genomics, Rockville MD.

For media inquires: Mrs. Aurélia Derischebourg, E: aurelia.derischebourg[.]crp-sante.lu.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific (thermo.com), which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Collaborates on Clinical Biomarker Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Scottpr.com 
+44(0)14 7753 9539
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing
STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award
BASF Pharma Solutions and IFF Pharma Solutions Establish Collaboration on Virtual Pharma Assistant Platform ZoomLab™

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  NexGen Unlimited, LLC





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)